Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Rhea-AI Summary
Actuate Therapeutics (NASDAQ: ACTU) announced that Dan Schmitt, President & CEO, will present at the Citizens Life Sciences Conference in Miami Beach on March 10, 2026 at 8:25 a.m. ET. The presentation will be webcast and available live under "Events" in Investors at the company website.
A replay will be available on Actuate's website for 30 days after the presentation, and management will hold one-on-one meetings with registered attendees.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ACTU fell 18.4% while key biotech peers showed mixed moves (e.g., CRDF up 4.21%, AVTX down 2.96%, GLSI down 1.85%). Only one peer (INO) appeared in the momentum scanner, moving up, which does not support a coordinated sector decline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Investor conference | Positive | +10.6% | Oppenheimer healthcare conference presentation with webcast and investor meetings. |
| Jan 21 | Clinical pipeline plan | Positive | +5.4% | Plan to start Phase 1/2 elraglusib tablet trial in refractory cancers. |
| Jan 12 | Phase 2 survival data | Positive | -6.3% | Phase 2 elraglusib plus GnP met primary endpoint in pancreatic cancer. |
| Jan 06 | Pediatric Phase 1 data | Positive | +5.0% | Positive outcomes in refractory pediatric cancers with elraglusib combinations. |
| Dec 18 | ASCO GI selection | Positive | +2.3% | Phase 2 pancreatic data selected for oral and poster presentation at ASCO GI. |
Recent Actuate news has generally been positive and often followed by gains, with one notable divergence on favorable Phase 2 data.
Over the last few months, Actuate has combined clinical progress with investor outreach. Positive clinical updates for elraglusib in metastatic pancreatic cancer and refractory pediatric cancers in January 2026 drove mixed price reactions, including a -6.35% move after strong Phase 2 survival data and gains of 5.4%, 5.05%, and 2.33% on other clinical milestones. A recent conference appearance on February 26, 2026 coincided with a 10.64% rise. Today’s Citizens Life Sciences Conference presentation continues this pattern of active visibility efforts.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration filed on 2025-09-02, allowing it to offer various securities such as common stock, debt, warrants, and units in the future. Specific offering terms and sizes are defined in subsequent prospectus supplements, with at least 2 such supplements (both Form 424B5) already filed.
Market Pulse Summary
This announcement highlights continued investor-relations activity, with Actuate presenting at the Citizens Life Sciences Conference on March 10, 2026 and offering a 30-day webcast replay. It follows recent clinical updates in pancreatic and pediatric cancers and another conference appearance in late February. Investors watching the story may focus on how these events support capital access, including use of the active S-3 shelf filed on 2025-09-02, and on future clinical milestones for elraglusib.
Key Terms
glycogen synthase kinase-3 beta (gsk-3β) medical
AI-generated analysis. Not financial advice.
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Citizens Life Sciences Conference in Miami Beach, FL on Tuesday, March 10, 2026, at 8:25 a.m. ET.
The webcast of Mr. Schmitt’s presentation will be available at:
The Actuate management team will be available for one-on-one meetings with registered conference attendees.
A live link to the presentation will be located under “Events” in the Investors section of the Company’s website at www.actuatetherapeutics.com. A replay of the webcast will be available on Actuate’s website for 30 days following the presentation.
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function.
For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.
Forward Looking Statements
This press release contains forward-looking statements about us, including our and other parties’ clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials and sub-group studies are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2026, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Reports on Form 10-Q, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310
FAQ
When will Actuate Therapeutics (ACTU) present at the Citizens Life Sciences Conference?
How can investors watch the ACTU presentation at the March 10, 2026 conference?
Will Actuate Therapeutics (ACTU) provide a replay of the Citizens Life Sciences presentation?
Who from Actuate will present at the Citizens Life Sciences Conference on March 10, 2026?
Where will the live webcast of Actuate Therapeutics (ACTU) be hosted for the conference presentation?
